Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $669K | $408K | $1.65M | $2.69M | $12.1K | $0.00 | — | $0.00 | $16.0M | $0.00 |
| Revenue growth | — | -39.1% | 305.5% | 62.5% | -99.6% | -100.0% | — | — | — | -100.0% |
| Operating income | — | — | -$10.8M | — | -$8.21M | -$14.2M | -$12.3M | -$12.6M | $4.51M | -$12.8M |
| Operating margin | — | — | -656.3% | — | -68104.8% | — | — | — | 28.2% | — |
| Net income | -$13.3M | -$13.2M | -$10.8M | -$7.10M | -$8.09M | -$13.8M | -$13.6M | -$12.5M | $3.59M | -$10.8M |
| Net margin | -1993.8% | -3243.5% | -654.2% | -264.2% | -67102.9% | — | — | — | 22.4% | — |
| EPS (diluted) | -$1.51 | -$0.93 | -$4.57 | -$2.23 | -$1.77 | -$57.12 | -$18.55 | -$24.25 | $0.87 | -$2.64 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.41M | -$6.47M | -$10.8M | -$8.15M | -$7.32M | -$10.7M | -$10.4M | -$9.56M | $8.56M | -$9.96M |
| Capital expenditures | $0.00 | $37.0K | $20.0K | $0.00 | $20.1K | $63.9K | $0.00 | $0.00 | $6.26K | $111K |
| Free cash flow | -$8.41M | -$6.51M | -$10.9M | -$8.15M | -$7.34M | -$10.7M | -$10.4M | -$9.56M | $8.55M | -$10.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.64M | $7.81M | $8.00M | $3.78M | $1.19M | $7.85M | $5.96M | $2.45M | $3.79M | $8.70M |
| Total assets | $9.73M | $14.3M | $14.3M | $10.1M | $15.2M | $20.1M | $18.7M | $13.7M | $36.5M | $24.3M |
| Total liabilities | $10.1M | $16.2M | $5.34M | $3.49M | $8.16M | $5.55M | $7.27M | $7.60M | $10.7M | $8.13M |
| Long-term debt | — | — | — | $0.00 | $278K | — | — | — | — | — |
| Shareholders' equity | -$329K | -$1.93M | $8.94M | $6.62M | $9.73M | $14.6M | $11.4M | $6.11M | $25.8M | $16.1M |
| Retained earnings | -$78.6M | -$91.8M | -$93.2M | -$100M | -$108M | -$121M | -$134M | -$147M | -$143M | -$154M |
| Shares (wtd avg diluted) | 10.1M | 17.3M | 3.04M | 4.08M | 4.58M | 241K | 732K | 538K | 4.13M | 4.10M |
Every figure is extracted from KIORA PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.